http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103319409-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2013-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103319409-B |
| titleOfInvention | A kind of edaravone compound, its pharmaceutical composition and preparation method thereof |
| abstract | The invention belongs to medical art, be specifically related to a kind of edaravone compound, the structural formula of described edaravone compound is:n the X-ray powder diffractogram that described edaravone compound uses the measurement of Cu-K alpha-ray to obtain as shown in Figure 1.Present invention also offers a kind of preparation method of the described preparation method of edaravone compound, the pharmaceutical composition containing this edaravone compound and this pharmaceutical composition.The formulation of described Edaravone medicine is injection with small volume and high-capacity injection.Edaravone compound provided by the invention has larger solubleness, dissolution rate is fast, and its pharmaceutical composition has better solubility property, and be easy to dissolve and compatibility, bioavailability is high. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020212748-A1 |
| priorityDate | 2013-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.